Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
Status:
Completed
Trial end date:
2021-03-11
Target enrollment:
Participant gender:
Summary
To demonstrate the clinical efficacy, safety and tolerability of secukinumab compared to
placebo in patients with nr-axSpA at Week 16 as well as Week 52 and long term efficacy and
safety up to Week 104 followed by an optional 16-week randomized dose escalation treatment
period and a continuous treatment period for up to Week 208